David A. Siegel Kintara Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.31 - $0.55 $9,331 - $16,555	-30,100 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.51 - $1.04 $15,351 - $31,304	30,100 New	30,100 $15,000
Q3 2021 Nov 15, 2021	SELL	$0.82 - $2.3 $8,293 - $23,262	-10,114 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.26 - $2.4 $12,743 - $24,273	10,114 New	10,114 $23,000

Ticker KTRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,807,296
Market Cap $17.8M
Description
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.